Return to Listing

237 result(s) for

PI Name Protocol # Title
V Liana Tsikitis IRB00003082 Oregon Colorectal Cancer Registry
Brett Sheppard IRB00003609 Oregon Pancreas Tissue Registry
Wei Huang IRB00004840 Quantitative Dynamic Contrast-Enhanced Breast MRI
Skye Mayo IRB00005222 Oregon Liver Tumor Registry
Zahi Mitri IRB00006256 [Wake Forest IRB - IREx] I-SPY 2 TRIAL: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2
Rebecca Silbermann IRB00008820 Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
Eva Medvedova IRB00009398 A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
Rodney Pommier IRB00009420 Oregon Index of Endocrine Neoplasias (ORION)
Erin Gilbert IRB00009694 The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer
Julie Graff IRB00009892 A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
Lara Davis IRB00010529 SARC024: A blanket protocol to study oral regorafenib in patients with selected sarcoma subtypes
Michael Heinrich IRB00010537 A Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Sancy Leachman IRB00010561 War on Melanoma: Enlisting a cohort of melanoma survivors and their families
Daniel Herzig IRB00011161 A Phase II Multicenter Randomized Trial Evaluating 3-Year Disease-Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy, and Total Mesorectal Excision or Non-Operative Management
Gina Vaccaro IRB00011256 Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer
Stephen Spurgeon IRB00011800 Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Brandon Hayes-Lattin IRB00011960 Long Term Follow-Up of Patients Exposed to Lentiviral- Based CAR T-Cell Therapy
Lara Davis IRB00012039 Sarcoma Survivorship Registry
Sancy Leachman STUDY00015038 Melanoma Tissue Bank Consortium: A Multi-Center Repository of Biospecimens and Data for Future Use
Charles Lopez STUDY00015304 CC #144525: Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
Adel Kardosh STUDY00015495 A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Jeremy Cetnar STUDY00015662 CA209-451: A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy
Kerri Winters STUDY00015921 INTense Exercise foR surviVAL among men with Metastatic Prostate Cancer (INTERVAL-GAP4): A Multicenter, Randomized, Controlled, Phase III Study
Rachel Cook STUDY00015977 [NCI CIRB] The National Myelodysplastic Syndromes (MDS) Study
Skye Mayo STUDY00016033 A Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma
Gordon Mills STUDY00016113 Molecular Mechanisms of Tumor Evolution and Resistance to Therapy
Elie Traer STUDY00016142 A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation, With a Substudy in Subjects With Relapsed or Refractory Myelodysplastic Syndrome and a Substudy in Subjects With Advanced Hematologic Malignancies With Organ Impairment
Richard Maziarz STUDY00016189 A Phase 1 Non-Randomized, Open-Label/Phase 2 Randomized, Blinded Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies
Jeremy Cetnar STUDY00016230 A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in combination with Ipilimumab placebo Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Ronan Swords STUDY00016475 A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Ronan Swords STUDY00016492 Targeting CD200 with Samalizumab to Enhance Outcomes in Elderly Untreated Core-Binding Factor Acute Myeloid Leukemia
Ronan Swords STUDY00016493 Phase 1b/2 Study of BI 836858 with Azacitidine in Previously Untreate AML Patients >60 Years With Unique Molecular Features
Jacqueline Vuky STUDY00016506 A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma
Julie Graff STUDY00016728 Advanced ChemoHormonal Therapy for Treatment Naïve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate with Prednisone and Androgen Deprivation Therapy after Treatment with Docetaxel and Androgen Deprivation Therapy
Michael Heinrich STUDY00016941 Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Ronan Swords STUDY00016962 A Phase II Study to Assess the Efficacy of the Treatment of IDH2 Mutant AML with Targeted IDH2 Inhibition and Subsequent Response-Driven Addition of Hypomethylating Agent Therapy
Ronan Swords STUDY00016963 A Phase 1b/2 Study of Entospletinib (ENTO) in Patients with Acute Myeloid Leukemia (AML) > Age 60 with MLL gene rearrangements and/or MLL-Partial Tandem Duplications (MLL-PTD)
Elie Traer STUDY00016964 A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
Rachel Cook STUDY00016984 A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Relapsed/Refractory Myelodysplastic Syndromes
Charles Lopez STUDY00017094 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Michael Heinrich STUDY00017155 A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients with Advanced Malignancies
Lara Davis STUDY00017190 A phase 1B trial of preoperative eribulin and radiation for retroperitoneal liposarcoma
Zahi Mitri STUDY00017461 [NCI CIRB] A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Jacqueline Vuky STUDY00017504 MonarchE: Protocol 13Y-MC-JPCF A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Ronan Swords STUDY00017569 A Phase 2 Study of Entospletinib and Decitabine Targeting Mutant TP53 and or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia > Age 60 years
Ronan Swords STUDY00017570 A Phase 2 Study of Entospletinib in NPM1 mutant/FLT3 ITD Wild Type AML Patients Age > 60 years
Eric Anderson STUDY00017574 A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial
Elie Traer STUDY00017577 A Phase 1/1b/2a, 3-Part, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination with Venetoclax in Subjects with Relapsed or Refractory Hematologic Malignancies
Eva Medvedova STUDY00017623 A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma
Rajan Kulkarni STUDY00017648 VAPORHCS/OHSU J: Isolation and analysis of circulating tumor cells (CTCs) and nucleic acids from patient blood specimens
Jeremy Cetnar STUDY00017685 CA209-816 - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
Tom Beer STUDY00017717 VAPORHCS/OHSU J: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Charles Lopez STUDY00017751 Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer
Kyaw Thein STUDY00017753 A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Craig Okada STUDY00017796 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma
Craig Okada STUDY00017820 A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Julie Graff STUDY00017864 TRITON3: A Multicenter, Randomized, Open-Label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Deficiency (protocol CO-338-063)
Zahi Mitri STUDY00017887 A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
Kerri Winters STUDY00018000 Exercising Together: A randomized controlled trial of partnered exercise training on the health of couples coping with cancer
Timur Mitin STUDY00018029 Prophylactic Tumor Treating Fields in Management of Patients with Small Cell Lung Cancer
Ronan Swords STUDY00018059 A Phase I/II, open-label, multi-center study evaluating the safety and efficacy of Ruxolitinib and CPX-351 in combination for the treatment of Advanced Phase Myeloproliferative Neoplasms.
Ronan Swords STUDY00018109 Phase 2 Study with Pevonedistat in combination with Azacitidine targeting NEDD8-activating enzyme (NAE) in TP53 Mutant Untreated Acute Myeloid Leukemia patients ≥ 60 years of age
Lara Davis STUDY00018118 A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3011 ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS
Tom Beer STUDY00018231 Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Jennifer Saultz STUDY00018238 Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Stephen Spurgeon STUDY00018251 An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Rachel Cook STUDY00018253 A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies
Andy Chen STUDY00018286 [NCI CIRB] A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Adel Kardosh STUDY00018340 A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Kerri Winters STUDY00018342 A novel therapeutic intervention to restore health and functioning in persons with chemotherapy-induced peripheral neuropathy
Kerri Winters STUDY00018354 Group Exercise Training for Fall Prevention and Functional Improvements During and After Treatment for Prostate Cancer
Rachel Cook STUDY00018380 An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Eva Medvedova STUDY00018388 [NCI CIRB] S1702, A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
Elie Traer STUDY00018399 Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
Ronan Swords STUDY00018440 Phase 2 Study of AG-120 combined with Azacitidine in Previously Untreated AML Patients > 60 Years with an IDH1 Mutation
Zahi Mitri STUDY00018504 A Phase II, Open Label, Study of Olaparib and Durvalumab in Patients with Metastatic Triple Negative Breast Cancer
Ronan Swords STUDY00018590 [WCG IRB - IAA] Gilteritinib Monotherapy or in Combination with Decitabine in Elderly Untreated FLT3 mutated Acute Myeloid Leukemia With High and Low Variant Allele Frequency (VAF) (Group 1) OR Gilteritinib in Combination with Decitabine and Venetoclax in Untreated FLT3 mutated Acute Myeloid Leukemia age ≥18 years or older With High and Low Variant Allele Frequency (VAF) (Group 2)
Jessica Leonard STUDY00018659 A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Ronan Swords STUDY00018684 Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin (Mylotarg) in Combination with Cytarabine, Anthracycline and Midostaurin Induction for Patients with Newly Diagnosed FLT3 Positive Acute Myeloid Leukemia (AML)
Skye Mayo STUDY00018937 A Phase II Trial of Perioperative CV301 Vaccination in Combination with Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer
Jeremy Cetnar STUDY00019009 A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
Zahi Mitri STUDY00019078 [NCI CIRB] S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Charles Lopez STUDY00019095 A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
Charles Lopez STUDY00019211 A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients with Pancreatic Ductal Adenocarcinoma
Brandon Hayes-Lattin STUDY00019250 [NCI CIRB] A041501 - A Phase III Trial To Evaluate the Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell All
Michael Heinrich STUDY00019262 A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)
Jennifer Saultz STUDY00019290 A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Adel Kardosh STUDY00019296 A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer
Michael Heinrich STUDY00019316 [MCW IRB-CML MOU] Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients who Relapsed After a Prior Attempt at TKI Discontinuation
Jeremy Cetnar STUDY00019330 A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)
Rachel Cook STUDY00019339 Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) therapy and control sub groups: combination of Mitoxantrone, Etoposide and Cytarabine (MEC) and combination of Fludarabine, Cytarabine, and Filgrastim (FLAG) in Older Patients (≥ 50 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Stephen Spurgeon STUDY00019363 A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects with Hematological Malignancies
Lara Davis STUDY00019380 An open-label, multi-institutional phase 0 study to assess the use of glucarpidase in patients with osteosarcoma receiving high-dose methotrexate
Stephen Spurgeon STUDY00019402 A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Jeremy Cetnar STUDY00019434 [NCI CIRB] LUNGMAP - A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
Levanto Schachter STUDY00019502 A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
Jeremy Cetnar STUDY00019505 A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
Julie Graff STUDY00019558 A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Charles Lopez STUDY00019576 Phase 1b Study to Assess the Safety of Neoadjuvant TAS-102 (triFluridine/tIpiracil) with ConcurrEnt Radiation in Previously Untreated Resectable Stage II and Stage III ReCtal CancEr (FIERCE)
Charles Lopez STUDY00019620 A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
Christopher Ryan STUDY00019661 [NCI CIRB] EA8143 (PROSPER): A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
Julie Graff STUDY00019692 A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
Stephen Spurgeon STUDY00019708 [NCI CIRB] EA9161 - A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Erik Mittra STUDY00019720 WIRB - IAA: A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma
Richard Maziarz STUDY00019760 A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9 Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies
Arthur Hung STUDY00019787 A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE)
Stephen Spurgeon STUDY00019800 [NCI CIRB] - A041702 - A RANDOMIZED PHASE III STUDY OF IBRUTINIB PLUS OBINUTUZUMAB VERSUS IBRUTINIB PLUS VENETOCLAX AND OBINUTUZUMAB IN UNTREATED OLDER PATIENTS (≥ 70 YEARS OF AGE) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Michael Heinrich STUDY00019801 [NCI CIRB] - S1712 - A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
Zahi Mitri STUDY00019830 A Single Arm Phase II Study to Evaluate Efficacy of T-DM1 with Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
Rebecca Silbermann STUDY00019855 A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Gabrielle Meyers STUDY00019856 A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF EQ001 IN SUBJECTS WITH NEWLY DIAGNOSED ACUTE GRAFT VERSUS HOST DISEASE
Richard Maziarz STUDY00019906 Long-Term Follow Up Protocol for Subjects Treated with Gene-Modified T Cells
Brandon Hayes-Lattin STUDY00019907 [NMDP - BMT CTN MOU] 1702: Clinical Transplant Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)
Eva Medvedova STUDY00019913 A Phase 1, Multicenter, Open-Label, Dose Finding Study of CC 99712, A BCMA Antibody-Drug Conjugate, in Subjects with Relapsed and Refractory Multiple Myeloma
Jennifer Saultz STUDY00019915 [NMDP - BMT CTN MOU] CTN 1704: Composite Health Assessment Model for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation (CHARM)
Aimee Kohn STUDY00019943 A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA
Elie Traer STUDY00019978 A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Christopher Ryan STUDY00019991 [NCI CIRB] A031704 - PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Christopher Ryan STUDY00019992 [NCI CIRB] MATCH - EAY131 - Molecular Analysis for Therapy Choice (MATCH)
Eva Medvedova STUDY00019993 [NCI CIRB] - EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Elie Traer STUDY00020009 A Multicenter, Phase 1, open-label study of the FGFR inhibitor pemigatinib (INCB054828) administered after chemotherapy in newly diagnosed Acute Myeloid Leukemia (AML) with adverse or intermediate risk cytogenetics
Bill Chang STUDY00020018 A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy.
Eneida Nemecek STUDY00020074 A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA)
Charles Lopez STUDY00020075 [NCI CIRB] EA2165 - A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Zahi Mitri STUDY00020112 Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Christopher Ryan STUDY00020148 A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
Christopher Ryan STUDY00020229 [NCI CIRB] A031702 - A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Eva Medvedova STUDY00020230 [NCI CIRB] S1803: PHASE III STUDY OF DARATUMUMAB/rHuPH20 (NSC- 810307) + LENALIDOMIDE OR LENALIDOMIDE AS POST-AUTOLOGOUS STEM CELL TRANSPLANT MAINTENANCE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA (MM) USING MINIMAL RESIDUAL DISEASE TO DIRECT THERAPY DURATION (DRAMMATIC STUDY)
Rachel Cook STUDY00020254 A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia
Tom Beer STUDY00020325 [Advarra - IAA] A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy
Charles Lopez STUDY00020357 [NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Eneida Nemecek STUDY00020379 Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
Adel Kardosh STUDY00020410 A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION
Zahi Mitri STUDY00020440 A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies
Tom Beer STUDY00020481 VAPORHCS/OHSU J: A randomized, open-label, multicenter, Phase 2b study to evaluate physical function, including balance and daily activity, in participants with castration-resistant prostate cancer treated with darolutamide or enzalutamide (Bayer 20609)
Craig Okada STUDY00020485 [NCI CIRB] S1826 - A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA
Kiri Cook STUDY00020501 A Randomized Trial of Standard Verbal Counseling with or without a Pictorial Educational Tool to Reduce Psychological Morbidity in Women Receiving Breast Radiation Therapy
Charles Lopez STUDY00020506 A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma
Rajan Kulkarni STUDY00020518 CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY
Laura Newell STUDY00020531 A Phase 1b trial of CPX-351 Lower Intensity Therapy (LIT) plus Venetoclax as First Line Treatment for Subjects with AML who are Unfit for Intensive Chemotherapy
Rachel Cook STUDY00020577 [Fred Hutch – SMART IRB]: Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality after Allogenic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients with Hematological Disease
Rachel Cook STUDY00020588 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)
Emerson Chen STUDY00020600 A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
Levanto Schachter STUDY00020643 A Phase 1, Multicenter, Open-Label Study of CC-97540, CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Jacqueline Vuky STUDY00020692 A Phase 1/2, open-label, dose escalation and cohort expansion clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in patients with metastatic castration-resistant prostate cancer
Arpita Gandhi STUDY00020708 A Multicenter Phase Ib Trial for Patients with Advanced Hematologic Malignancies undergoing Allogeneic Hematopoietic Cell Transplantation with Orca-T, a T-cell-Depleted Graft with Additional Infusion of Conventional T cells and Regulatory T cells
Ronan Swords STUDY00020736 A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL)
Khashayar Farsad STUDY00020744 A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)
Adel Kardosh STUDY00020747 MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer
Richard Maziarz STUDY00020759 A Phase 1 Dose Escalation and Cohort Expansion Study of Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects with Relapsed or Refractory Multiple Myeloma
Levanto Schachter STUDY00020763 A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety of BB2121 in Subjects with High-Risk, Newly Diagnosed Multiple Myeloma (KarMMA-4)
Eva Medvedova STUDY00020886 [WCG IRB - IAA] A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma
Charles Lopez STUDY00020901 A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer
Anusha Vallurupalli STUDY00020930 [NCI CIRB] A051701 - Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Christopher Ryan STUDY00020946 A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
Lara Davis STUDY00020959 A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma - Expansion Cohort Segment Only
Christopher Ryan STUDY00020977 An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies
Adel Kardosh STUDY00020980 Phase II randomized multi-center trial of total neoadjuvant therapy with and without CD40 agonist, APX005M, for locally advanced rectal adenocarcinoma
Richard Maziarz STUDY00021119 An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients with Hematological Malignancies
Ronan Swords STUDY00021153 [WCG IRB- IAA] Phase 1b/2 Study of AZD5153 Combined with Venetoclax in Relapsed/Refractory (Phase 1b) and Previously Untreated AML Patients (Phase 2)
Ronan Swords STUDY00021154 [WCG IRB- IAA] Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥ Age 60 years
Shivaani Kummar STUDY00021194 A phase 1 study of SGN-CD228A in select advanced solid tumors
Stephen Spurgeon STUDY00021208 A Phase 1B, Multi-center, Open-label Study to determine the Safety, Pharmacokinetics, and Preliminary Efficacy of CC-99282 in combination with Obinutuzumab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Michael Heinrich STUDY00021229 Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Rachel Cook STUDY00021238 A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)
Zahi Mitri STUDY00021243 OHSU IIT: A Phase 1 Study of Abemaciclib and Niraparib as Neoadjuvant Therapy in Hormone Receptor Positive (HR+) HER2 Negative (HER2-) Breast Cancer
Zhenzhen Zhang STUDY00021253 Microbiome and Esophageal Cancer Progression (MEP) Study
Craig Okada STUDY00021258 Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
Jeremy Cetnar STUDY00021280 A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
Erika Cottrell STUDY00021282 Understanding the Experience of Adolescent and Young Adult Cancer (AYA Cancer Study)
Prakash Ambady STUDY00021284 (Advarra-IRB) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
Shivaani Kummar STUDY00021349 A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types
Richard Maziarz STUDY00021423 A Phase 1/2 Study of RTX-240 as a Monotherapy and in Combination with Pembrolizumab
Tom Beer STUDY00021438 PREEMPT CRC: PREvention Employing a Multiomics Plasma-based Test for ColoRectal Cancer
Rebecca Silbermann STUDY00021440 A Phase I Study to Evaluate the Pharmacokinetics and Safety of belantamab mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
Zahi Mitri STUDY00021441 EA1183: FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE
Levanto Schachter STUDY00021454 Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release.
Arpita Gandhi STUDY00021456 A Phase 1A/B Study to Evaluate the Safety and Tolerability of JSP191 in Combination with a Conditioning Regimen of Low Dose Radiation and Fludarabine in Subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT).
Shivaani Kummar STUDY00021464 A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade
Eva Medvedova STUDY00021488 A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
Eva Medvedova STUDY00021501 A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
Shivaani Kummar STUDY00021508 An Open-label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors
Shivaani Kummar STUDY00021548 A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors
Charles Lopez STUDY00021614 NeoOPTIMIZE: an open-label, phase II trial to assess the efficacy of adaptive switching of modified FOLFIRINOX or Gemcitabine/nab-Paclitaxel as a neoadjuvant strategy for patients with resectable and borderline resectable/ locally advanced unresectable pancreatic cancer.
Christopher Ryan STUDY00021677 [NCI CIRB] NCICOVID - NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Jessica Leonard STUDY00021691 Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR-105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant
Elie Traer STUDY00021730 ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome
Shivaani Kummar STUDY00021766 A Phase I/Ib Study to Evaluate the Safety, Tolerability, Biological and Clinical Activities of GEN-001 in Combination with Avelumab in Patients with Advanced Solid Tumors Who Have Progressed during or after Treatment with Anti-PD-(L)1 therapy
Jeremy Cetnar STUDY00021770 [NCI CIRB] EA5191: A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
Emerson Chen STUDY00021797 A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers
Rebecca Silbermann STUDY00021808 A Single Arm Phase II Study of Isatuximab with Carfilzomib and Pomalidomide in Relapsed or Refractory Multiple Myeloma
Shivaani Kummar STUDY00021819 A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Jessica Leonard STUDY00021851 Real World Observational Study using clonoSEQ Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry
Michael Heinrich STUDY00021884 An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Jeremy Cetnar STUDY00021886 A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Adel Kardosh STUDY00021972 A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)
Anusha Vallurupalli STUDY00021975 A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
Jennifer Saultz STUDY00021983 A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non–Hodgkin Lymphoma of B-Cell Origin
Shivaani Kummar STUDY00021998 A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation
Joseph Shatzel STUDY00021999 Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders
Anna Bar STUDY00022052 Prospective Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma
Elie Traer STUDY00022070 A Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination with All-Trans Retinoic Acid (ATRA) in Subjects with Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML)
Andy Chen STUDY00022072 [WIRB - IAA] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
Shivaani Kummar STUDY00022082 A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors
Elie Traer STUDY00022131 A Phase 1b Study of ABBV-744 Alone or in Combination with Ruxolitinib or Navitoclax in Subjects with Myelofibrosis
Lara Davis STUDY00022158 SARC038: A Phase 2 Study of Regorafenib in Combination with Nivolumab in Patients with Refractory or Recurrent Osteosarcoma
Jacqueline Vuky STUDY00022161 [NCI CIRB] S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Zahi Mitri STUDY00022179 The Breast Cancer Observational Study
Emerson Chen STUDY00022189 PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Zahi Mitri STUDY00022191 A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756)
Adel Kardosh STUDY00022198 The Gastrointestinal Cancer Observational Study (GICOS)
Nima Nabavizadeh STUDY00022220 [NCI CIRB] EA2182 - A Randomized Phase II Study of De-Intensified ChemoRadiation for EarlyStage Anal Squamous Cell Carcinoma (DECREASE)
Jeremy Cetnar STUDY00022221 [NCI CIRB] S1933 - A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status
Shivaani Kummar STUDY00022223 A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Zahi Mitri STUDY00022225 A Phase I/II Open-label, First-in-Human, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 Monotherapy in Adult Subjects with Advanced and/or Metastatic Hormone Receptor (HR)-positive, HER2-negative Breast Cancer
Adel Kardosh STUDY00022247 Establishing a ctDNA biomarker to improve organ preserving strategies in patients with rectal cancer
Kiri Cook STUDY00022257 [NCI CIRB] MA.39 - TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
Zahi Mitri STUDY00022388 A Single Arm Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer
Dale Han STUDY00022389 Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors: A Phase 1b/2 Study of Cavrotolimod Combined with Pembrolizumab or Cemiplimab
Zahi Mitri STUDY00022395 A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Stage II-III, Estrogen Receptor Positive, HER2-negative Breast Cancer (DARE)
Michael Heinrich STUDY00022463 [NCI CIRB] A021804 - A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA
Christopher Ryan STUDY00022464 [NCI CIRB] A091902 - A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA
Emerson Chen STUDY00022465 [NCI CIRB] EA2176 - A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients
Skye Mayo STUDY00022479 A SINGLE-ARM FEASIBILITY STUDY OF GEMCITABINE, CISPLATIN, AND NAB-PACLITAXEL AS NEOADJUVANT THERAPY FOR RESECTABLE ONCOLOGICALLY HIGH-RISK INTRAHEPATIC CHOLANGIOCARCINOMA
Rebecca Silbermann STUDY00022542 [NCI CIRB] EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation
Jessica Leonard STUDY00022552 [NCI CIRB] A041703: A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease
Jessica Leonard STUDY00022553 [NCI CIRB] S1905: A PHASE I/II STUDY OF AKR1C3-ACTIVATED PRODRUG OBI‐3424 (OBI-3424) IN PATIENTS WITH RELAPSED/REFRACTORY T‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) / T-CELL LYMPHOBLASTIC LYMPHOMA (T-LBL)
Shivaani Kummar STUDY00022580 CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
Stephen Spurgeon STUDY00022665 Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients with CLL/SLL
Elizabeth Berry STUDY00022704 Skin Fluorescent Imaging (SFI) System in Patients with Nevi (Orlucent SFI003)
Christopher Ryan STUDY00022759 [NCI CIRB] S1931: PHASE III TRIAL OF IMMUNOTHERAPY-BASED COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL)
Jeremy Cetnar STUDY00022772 [NCI CIRB] S1900E - A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Shivaani Kummar STUDY00022902 A PHASE 2, SUBPROTOCOL OF DAY101 MONOTHERAPY FOR PATIENTS WITH RECURRENT, PROGRESSIVE, OR REFRACTORY SOLID TUMORS WITH ACTIVATING BRAF GENE FUSION
Tom Beer STUDY00022989 Project Danube: Multi-Cancer and Comorbidity Blood Sample Collection for Cross-Reactivity Analysis for a Multiomics CRC Screening Test
Flavio Rocha STUDY00023005 [NCI CIRB] EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Ronan Swords STUDY00023052 [WCG IRB - IAA] A Phase 1b Study of AZD5991 + Azacitidine (AZA) in previously untreated patients ≥60 years with hypermethylation and marker Negative AML
Evan Shereck STUDY00023290 [NMDP IRB-MOU] Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080